Related Experiment Video
Updated: Jun 10, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
Anti-apoptotic protein BCL2 down-regulates DNA end joining in cancer cells
Tadi Satish Kumar1, Vijayalakshmi Kari, Bibha Choudhary
1Department of Biochemistry, Indian Institute of Science, Bangalore 560012, India.
Abstract:
Cancer cells are often associated with secondary chromosomal rearrangements, such as deletions, inversions, and translocations, which could be the consequence of unrepaired/misrepaired DNA double strand breaks (DSBs). Nonhomologous DNA end joining is one of the most common pathways to repair DSBs in higher eukaryotes. By using oligomeric DNA substrates mimicking various endogenous DSBs in a cell-free system, we studied end joining (EJ) in different cancer cell lines. We found that the efficiency of EJ varies among cancer cells; however, there was no remarkable difference in the mechanism and expression of EJ proteins. Interestingly, cancer cells with lower levels of EJ possessed elevated expression of BCL2 and vice versa. Removal of BCL2 by immunoprecipitation or protein fractionation led to elevated EJ. More importantly, we show that overexpression of BCL2 or the addition of purified BCL2 led to the down-regulation of EJ. Further, we found that BCL2 interacts with KU proteins both in vitro and in vivo. Hence, our results suggest that EJ in cancer cells could be negatively regulated by the anti-apoptotic protein, BCL2, and this may contribute toward increased chromosomal abnormalities in cancer.
Insights
Cancer cells exhibit varying DNA repair efficiency. The anti-apoptotic protein BCL2 negatively regulates DNA end joining (EJ), potentially increasing chromosomal abnormalities in cancer.
Area of Science:
- Molecular Biology
- Cancer Biology
- Genetics
Background:
- Chromosomal rearrangements in cancer cells may stem from unrepaired DNA double-strand breaks (DSBs).
- Nonhomologous DNA end joining (NHEJ) is a primary pathway for repairing DSBs in eukaryotes.
Purpose of the Study:
- To investigate the efficiency and regulation of DNA end joining (EJ) in various cancer cell lines.
- To explore the role of the anti-apoptotic protein BCL2 in regulating EJ.
Main Methods:
- Utilized cell-free systems with oligomeric DNA substrates to mimic DSBs.
- Assessed EJ efficiency across different cancer cell lines.
- Investigated BCL2 expression levels and its interaction with KU proteins.
Main Results:
- EJ efficiency varied among cancer cell lines without significant differences in EJ protein mechanisms or expression.
- Cancer cells with lower EJ efficiency showed higher BCL2 expression, and vice versa.
- BCL2 negatively impacts EJ; its removal elevated EJ, while its overexpression or addition reduced EJ.
- BCL2 was found to interact with KU proteins in vitro and in vivo.
Conclusions:
- The anti-apoptotic protein BCL2 negatively regulates DNA end joining (EJ) in cancer cells.
- BCL2's interaction with KU proteins may mediate this regulation.
- This BCL2-mediated down-regulation of EJ could contribute to increased chromosomal abnormalities observed in cancer.
Related Concept Videos
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Cellular Injury V: Apoptosis and Autophagy
Abnormal Proliferation
Apoptosis
DNA Damage can Stall the Cell Cycle